Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.
OBJECTIVES: The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA. METHODS: Symptoms were assessed over 3 years in patients with primary knee OA receiving strontium ranelate 2 g/day (n = 454), 1 g/day (n = 445) or placebo (n = 472) in the Strontium R...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2014
|
| _version_ | 1826263951773532160 |
|---|---|
| author | Bruyère, O Reginster, J Bellamy, N Chapurlat, R Richette, P Cooper, C |
| author_facet | Bruyère, O Reginster, J Bellamy, N Chapurlat, R Richette, P Cooper, C |
| author_sort | Bruyère, O |
| collection | OXFORD |
| description | OBJECTIVES: The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA. METHODS: Symptoms were assessed over 3 years in patients with primary knee OA receiving strontium ranelate 2 g/day (n = 454), 1 g/day (n = 445) or placebo (n = 472) in the Strontium Ranelate Efficacy in Knee Osteoarthritis Trial. Clinical response was evaluated using WOMAC subscores, minimal perceptible clinical improvement (MPCI), minimal clinically important improvement (MCII) and a modified OMERACT-Osteoarthritis Research Society International (OARSI) responder definition. Patients who withdrew prematurely from the study were considered non-responders. RESULTS: There was no significant effect on symptoms for strontium ranelate 1 g/day. At the dosage of 2 g/day, strontium ranelate was associated with greater response than placebo in terms of ≥20% improvement in WOMAC pain from baseline to the last visit (58% vs 47%, P = 0.002) and ≥50% improvement in WOMAC pain (42% vs 36%, P = 0.083). Significant differences were found in MPCI response for WOMAC pain (52% vs 40%, P < 0.001), stiffness (47% vs 39%, P = 0.009) and physical function (46% vs 37%, P = 0.009) and in MCII response for WOMAC physical function (46% vs 37%, P = 0.013). There were also more OMERACT-OARSI-like responders with strontium ranelate (44% vs 35%, P = 0.004). The treatment-placebo difference in MPCI response for WOMAC pain was significant after 6 months (P = 0.024), while that in MPCI and MCII response for WOMAC physical function reached significance after 12 months (P = 0.027 and P = 0.019, respectively). CONCLUSION: Treatment with strontium ranelate 2 g/day over 3 years is associated with a clinically meaningful improvement in pain from 6 months as well as physical function and stiffness as assessed by the number of responders above thresholds of clinical relevance. TRIAL REGISTRATION: Current Controlled Trials. http://www.controlled-trials.com/ (ISRCTN41323372). |
| first_indexed | 2024-03-06T20:00:03Z |
| format | Journal article |
| id | oxford-uuid:26f8c3a5-e7fd-46db-8b50-f4dcd8a6df22 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:00:03Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:26f8c3a5-e7fd-46db-8b50-f4dcd8a6df222022-03-26T12:04:10ZClinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:26f8c3a5-e7fd-46db-8b50-f4dcd8a6df22EnglishSymplectic Elements at Oxford2014Bruyère, OReginster, JBellamy, NChapurlat, RRichette, PCooper, COBJECTIVES: The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA. METHODS: Symptoms were assessed over 3 years in patients with primary knee OA receiving strontium ranelate 2 g/day (n = 454), 1 g/day (n = 445) or placebo (n = 472) in the Strontium Ranelate Efficacy in Knee Osteoarthritis Trial. Clinical response was evaluated using WOMAC subscores, minimal perceptible clinical improvement (MPCI), minimal clinically important improvement (MCII) and a modified OMERACT-Osteoarthritis Research Society International (OARSI) responder definition. Patients who withdrew prematurely from the study were considered non-responders. RESULTS: There was no significant effect on symptoms for strontium ranelate 1 g/day. At the dosage of 2 g/day, strontium ranelate was associated with greater response than placebo in terms of ≥20% improvement in WOMAC pain from baseline to the last visit (58% vs 47%, P = 0.002) and ≥50% improvement in WOMAC pain (42% vs 36%, P = 0.083). Significant differences were found in MPCI response for WOMAC pain (52% vs 40%, P < 0.001), stiffness (47% vs 39%, P = 0.009) and physical function (46% vs 37%, P = 0.009) and in MCII response for WOMAC physical function (46% vs 37%, P = 0.013). There were also more OMERACT-OARSI-like responders with strontium ranelate (44% vs 35%, P = 0.004). The treatment-placebo difference in MPCI response for WOMAC pain was significant after 6 months (P = 0.024), while that in MPCI and MCII response for WOMAC physical function reached significance after 12 months (P = 0.027 and P = 0.019, respectively). CONCLUSION: Treatment with strontium ranelate 2 g/day over 3 years is associated with a clinically meaningful improvement in pain from 6 months as well as physical function and stiffness as assessed by the number of responders above thresholds of clinical relevance. TRIAL REGISTRATION: Current Controlled Trials. http://www.controlled-trials.com/ (ISRCTN41323372). |
| spellingShingle | Bruyère, O Reginster, J Bellamy, N Chapurlat, R Richette, P Cooper, C Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. |
| title | Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. |
| title_full | Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. |
| title_fullStr | Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. |
| title_full_unstemmed | Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. |
| title_short | Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. |
| title_sort | clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis a responder analysis |
| work_keys_str_mv | AT bruyereo clinicallymeaningfuleffectofstrontiumranelateonsymptomsinkneeosteoarthritisaresponderanalysis AT reginsterj clinicallymeaningfuleffectofstrontiumranelateonsymptomsinkneeosteoarthritisaresponderanalysis AT bellamyn clinicallymeaningfuleffectofstrontiumranelateonsymptomsinkneeosteoarthritisaresponderanalysis AT chapurlatr clinicallymeaningfuleffectofstrontiumranelateonsymptomsinkneeosteoarthritisaresponderanalysis AT richettep clinicallymeaningfuleffectofstrontiumranelateonsymptomsinkneeosteoarthritisaresponderanalysis AT cooperc clinicallymeaningfuleffectofstrontiumranelateonsymptomsinkneeosteoarthritisaresponderanalysis |